Welcome to our dedicated page for Amgen SEC filings (Ticker: AMGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. reported stronger Q3 2025 results. Total revenues rose to $9,557 million from $8,503 million a year ago, driven by product sales of $9,137 million. Net income increased to $3,216 million and diluted EPS was $5.93 versus $5.22 last year, as operating income improved to $2,526 million.
Performance was supported by key brands including Prolia, TEPEZZA, EVENITY, Repatha, and Otezla. Other income remained elevated, reflecting unrealized gains on equity investments recorded in the period. Year-to-date, net cash provided by operating activities reached $8,355 million, while cash and cash equivalents were $9,445 million at quarter end. Long-term debt declined to $52,434 million from $56,549 million at year-end.
The effective tax rate increased to 18.0% for the quarter. Amgen recorded an additional $400 million noncash impairment to Otezla developed-product-technology rights in Q3 (total $1.2 billion year-to-date) following updates in Medicare price setting under the IRA.
Amgen Inc. furnished an 8-K announcing its third quarter 2025 results, with the full press release provided as Exhibit 99.1. The release includes unaudited operating results for the three and nine months ended September 30, 2025 and the company’s financial position as of that date.
Amgen presented non-GAAP metrics alongside GAAP, including non-GAAP EPS, operating income, operating margin, tax rate, operating expenses (and sub-components), and Free Cash Flow, with reconciliations to GAAP included. Adjustments cover acquisition-related expenses, restructuring and cost savings initiatives, certain investment gains/losses, specified legal items, and related tax effects. The information is furnished, not filed, under Item 2.02.
Amgen Inc: The Vanguard Group reports beneficial ownership of 53,860,795 shares of Amgen common stock, representing 10% of the class. Vanguard states it has sole dispositive power over 48,671,065 shares and shared dispositive power over 5,189,730 shares, with shared voting power for 3,134,008 shares and no sole voting power. The filing is submitted on a Schedule 13G/A and includes a certification that the holdings are in the ordinary course of business and not intended to influence control of the issuer.
Nancy A. Grygiel, SVP & CCO of Amgen Inc. (AMGN), reported a sale of common stock on 08/20/2025. The filing shows 1,267 shares were disposed of at a price of $296.985 per share. After this transaction the reporting person directly beneficially owned 7,209 shares.
The filing also discloses an indirect interest of 103.8077 shares held through Amgen's 401(k) plan. The report notes that 80 dividend equivalents were credited to unvested RSUs and are paid in shares per the company plan.
Amgen Inc. (AMGN) Form 144 notice reports a proposed sale of 1,267 shares of common stock through Raymond James & Associates on 08/20/2025 with an aggregate market value of $372,908.81. The shares were acquired from the issuer on 03/18/2024 via RSE/DEU grants and paid in cash. The filing lists 538,360,000 shares outstanding. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Amgen director S. Omar Ishrak reported the acquisition of 121.4308 shares of Amgen common stock on 08/08/2025 via vested restricted stock units under the Amgen Inc. 2009 Director Incentive Program. The transaction is shown at a $0 price, reflecting issuance of shares upon vesting, and the Form 4 was signed on 08/09/2025.
The filing reports 6,241.9302 shares beneficially owned following the transaction, held directly. The reported shares include 291 Dividend Equivalents credited to vested but deferred RSUs and payable in shares under a dividend reinvestment arrangement. The document identifies the reporting person as a director of Amgen (AMGN).
On 08/08/2025 Amgen director Charles M. Holley reported the immediate vesting of restricted stock units (RSUs) granted under Amgen's Director Incentive Program. The vested RSUs were converted to common stock on a one-for-one basis and recorded as an acquisition (transaction code A) with a reported price of $0.
Following the reported transaction Holley beneficially owns 11,469.6259 shares directly and 1,260 shares indirectly through the Holley Family Trust. The filing also shows 1,294 Dividend Equivalents credited to vested but deferred RSUs, which are payable in shares one-for-one with cash for any fractional share amounts.
Michael V. Drake, a director of Amgen Inc. (AMGN), reported the vesting and conversion of Restricted Stock Units into 121.4308 shares on 08/08/2025. The vested RSUs convert one-for-one into common stock and were reported at a purchase price of $0, reflecting compensation rather than an open-market trade. After the transaction his direct beneficial ownership is reported as 4,699.0291 shares. The reported amount includes 227 Dividend Equivalents credited on vested-but-deferred RSUs that are paid in shares under the Director Incentive Program and the Amgen Inc. 2009 Equity Incentive Plan.